Chiron Vision Submits Laser PMA.CLAREMONT, Calif.--(BW HealthWire)--Nov. 21, 1997--Chiron Corporation's (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CHIR) Claremont-based ophthalmic surgical company Chiron Vision today announced that it has submitted to FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. a Premarket Application (PMA) seeking approval to market its Technolas excimer laser system for photorefractive keratectomy (PRK). PRK is a procedure which uses the excimer laser to remove tissue from the surface of the eye for correction of myopia (nearsightedness nearsightedness or myopia, defect of vision in which far objects appear blurred but near objects are seen clearly. Because the eyeball is too long or the refractive power of the eye's lens is too strong, the image is focused in front of the ) and astigmatism. The Chiron Vision application to FDA includes clinical data on over 1,000 eyes treated for 1 to 10 diopters of myopia and up to 4.5 diopters of astigmatism. The Technolas Laser is one of the leading excimer laser systems in the world with installations in locations ranging from China and the Asia-Pacific to Canada, South America and throughout Europe, the Middle East and Africa Europe, the Middle East and Africa, usually abbreviated to EMEA, is a regional designation used for government, marketing and business purposes. It is particularly common amongst North American based companies, who often divide their international operations into the . The Technolas system is used by refractive surgeons to correct myopia, hyperopia, myopic and hyperopic astigmatism in any combination. Chiron Vision is a division of Chiron Corporation headquartered in Emeryville, California, a science-driven, market-directed healthcare company. Chiron participates in four global health-care markets: diagnostics, therapeutics, pediatric pediatric /pe·di·at·ric/ (pe?de-at´rik) pertaining to the health of children. pe·di·at·ric adj. Of or relating to pediatrics. and adult vaccines and ophthalmic products. Chiron also conducts research and development in the fields of biological proteins, gene therapy and combinatorial chemistry. Chiron Vision, headquartered in Claremont, California, researches, develops , manufactures and markets products for the surgical correction of vision, including intraocular lenses (IOLs) phacoemulsification phacoemulsification /phaco·emul·si·fi·ca·tion/ (-e-mul?si-fi-ka´shun) a method of cataract extraction in which the lens is fragmented by ultrasonic vibrations and simultaneously irrigated and aspirated. instruments, viscoelastics, corneal shapers, excimer lasers and drug delivery systems. Chiron Vision is among the world's leading sellers of IOLs and related products. CONTACT: Chiron Corporation Jim Knighton, 510/923-6055 or Chiron Vision Missy Lowery, 909/399-1258 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion